Indaptus Therapeutics, Inc. (INDP)
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$20.8M
- Total assets
- $9.3M
- Market cap
- $414.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $16.4M
- Operating income
- -$16.4M
- Income tax
- $2.5K
- Net income
- -$15.4M
- EPS (basic)
- $-1.83
- EPS (diluted)
- $-1.83
Balance sheet
- Total assets
- $14.9M
- Current assets
- $14.0M
- Total liabilities
- $2.8M
- Current liabilities
- $2.8M
- Shareholders’ equity
- $12.1M
Cash flow
- Operating cash flow
- -$13.4M
- Investing cash flow
- $17.1M
- Financing cash flow
- -$3.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $414.5M
- EPS (diluted)
- $-1.83
- Shares outstanding
- 158.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 4, 2021
Indaptus Therapeutics, Inc. (INDP) Stock Price
- Reported a net loss of $20.8M.
- Trading 81% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Indaptus Therapeutics, Inc..
Write a review
News about Indaptus Therapeutics, Inc.
News & sentiment via Polygon.io
Indaptus Therapeutics, Inc.: frequently asked questions
Is Indaptus Therapeutics, Inc. an American company?
Indaptus Therapeutics, Inc. is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Indaptus Therapeutics, Inc. headquartered?
Indaptus Therapeutics, Inc. is headquartered in New York, New York, United States.
Is Indaptus Therapeutics, Inc. publicly traded?
Yes — Indaptus Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol INDP on the NASDAQ.
What does Indaptus Therapeutics, Inc. do?
Indaptus Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
